secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001654954-22-016272
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences to effect 1-for-20 reverse stock split on Dec 9, 2022
-------------------------------------------------------------------------

- Stockholders approved the 1-for-20 reverse split at a special meeting on November 29, 2022.
- Effective 12:01 a.m. ET Dec 9; every 20 outstanding shares become 1 share; fractional shares rounded up.
- Authorized shares remain 80M; exercise price and share counts for outstanding options proportionally adjusted.
- Common stock will trade on Nasdaq on a split-adjusted basis under symbol NDRA; new CUSIP 29273B302.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/0001654954-22-016272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-016272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer